Файл: kinins - review.pdf

ME Moreau et al

36

236 Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E.

Omapatrilat and enalapril in patients with hypertension: the
Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE)
trial. Am J Hypertens. 2004;17:103–111.

237 Zanchi A, Maillard M, Burnier M. Recent clinical trials with

omapatrilat: new developments. Curr Hypertens Rep. 2003;5:
346–352.

238 Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ,

Rouleau JL, et al. Comparison of omapatrilat and enalapril in
patients with chronic heart failure: the Omapatrilat Versus
Enalapril Randomized Trial of Utility in Reducing Events
(OVERTURE). Circulation. 2002;106:920–926.

239 Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D. Compari-

son of a vasopeptidase inhibitor with neutral endopeptidase and

angiotensin-converting enzyme inhibitors on bradykinin metabo-
lism

 in the rat coronary bed. J Cardiovasc Pharmacol. 2001;

37:359–366.

240 Raut R, Rouleau JL, Blais C Jr, Gosselin H, Molinaro G, Sirois

MG, et al. Bradykinin metabolism in the postinfarcted rat heart:
role of ACE and neutral endopeptidase 24.11. Am J Physiol.
1999;276:H1769–H1779.

241 Dumoulin MJ, Lamontagne D, Burnett J, Heublein D,

Yamaguchi N, Adam A. Respective role of endogenous kinins
and natriuretic peptides in the cardioprotective effect of
omapatrilat following total heart ischemia (abstract). Eur Heart
J. 2001;22:50.

242 Bralet J, Schwartz JC. Vasopeptidase inhibitors: an emerging

class of cardiovascular drugs. Trends Pharmacol Sci. 2001;22:
106–109.

243 Dumoulin MJ, Adam A, Burnett J, Heublein D, Yamaguchi N,

Lamontagne D. The cardioprotective effect of dual metallo-
peptidase inhibition: respective roles of endogenous kinins and
natriuretic peptides. Can J Physiol Pharmacol. 2005;83:166–173.

244 Hill MD, Barber PA, Takahashi J, Demchuk AM, Feasby TE,

Buchan AM. Anaphylactoid reactions and angioedema during
alteplase treatment of acute ischemic stroke. Cmaj. 2000;162:
1281–1284.

245 Molinaro G, Adam A, Lepage Y, Hammerschmidt D,

Koenigbauer U, Eastlund T. Hypotensive reaction during
staphylococcal protein A column therapy in a patient with
anomalous degradation of bradykinin and Des-Arg9-bradykinin
after contact activation. Transfusion. 2002;42:1458–1465.

246 Coletta A, Thackray S, Nikitin N, Cleland JG. Clinical trials

update: highlights of the scientific sessions of The American
College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2,
MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2,

CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH

,

BNP trial and HARDBALL. Eur J Heart Fail. 2002;4:381–388.

247 Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni

A. Aminopeptidase P in individuals with a history of angio-
oedema on ACE inhibitors. Lancet. 2002;359:2088–2089.

248 Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni

A, et al. Angiotensin-converting enzyme Inhibitor-associated
angioedema is characterized by a slower degradation of des-
Arginine9-Bradykinin. J Pharmacol Exp Ther. 2002;303:232–
237.

249 Arnold DM, Molinaro G, Warkentin TE, DiTomasso J, Webert

KE, Davis I, et al. Hypotensive transfusion reactions can occur
with blood products that are leukoreduced before storage.
Transfusion. 2004;44:1361–1366.

250 Duan Q, Nikpoor B, Molinaro G, Meijer I, Rochefort D, Saint-

Onge J, et al. Variants in XPNPEP2 increase susceptibility to
ACE-inhibitor associated adverse reactions. Am J Hum Genet.
In press 2005.

251 Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons

WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with
ACE-inhibitor-associated angioedema. Hypertension. 2002;39:
460–464.

252 Houle S, Landry M, Audet R, Bouthillier J, Bachvarov DR,

Marceau F. Effect of allelic polymorphism of the B(1) and B(2)
receptor genes on the contractile responses of the human
umbilical vein to kinins. J Pharmacol Exp Ther. 2000;294:45–
51.

253 Pe’er I, Beckmann JS. On the applicability of a haplotype map to

un-assayed populations. Hum Genet. 2004;114:214–217.

254 Hess JF, Hey PJ, Chen TB, Pettibone DJ, Chang RS. Molecular

and pharmacological diversity of the kinin B1 receptor. Int
Immunopharmacol. 2002;2:1747–1754.

255 Brull D, Dhamrait S, Myerson S, Erdmann J, Woods D, World

M, et al. Bradykinin B2BKR receptor polymorphism and left-
ventricular growth response. Lancet. 2001;358:1155–1156.

256 Hallberg P, Lind L, Michaelsson K, Karlsson J, Kurland L,

Kahan T, et al. B2 bradykinin receptor (B2BKR) polymorphism
and change in left ventricular mass in response to antihyper-
tensive treatment: results from the Swedish Irbesartan Left

Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA

)

trial. J Hypertens. 2003;21:621–624.

257 Williams AG, Dhamrait SS, Wootton PT, Day SH, Hawe E,

Payne JR, et al. Bradykinin receptor gene variant and human
physical performance. J Appl Physiol. 2004;96:938–942.

258 Dhamrait SS, Payne JR, Li P, Jones A, Toor IS, Cooper JA, et al.

Variation in bradykinin receptor genes increases the cardio-
vascular risk associated with hypertension. Eur Heart J. 2003;
24:1672–1680.

259 Maltais I, Bachvarova M, Maheux P, Perron P, Marceau F,

Bachvarov D. Bradykinin B2 receptor gene polymorphism is
associated with altered urinary albumin

/

creatinine values in

diabetic patients. Can J Physiol Pharmacol. 2002;80:323–327.

260 Zee RY, Rao VS, Paster RZ, Sweet CS, Lindpaintner K. Three

candidate genes and angiotensin-converting enzyme inhibitor-
related cough: a pharmacogenetic analysis. Hypertension. 1998;
31:925–928.

261 Cui J, Melista E, Chazaro I, Zhang Y, Zhou X, Manolis AJ, et al.

Sequence variation of bradykinin receptors B1 and B2 and
association with hypertension. J Hypertens. 2005;23:55–62.

262 Gainer JV, Brown NJ, Bachvarova M, Bastien L, Maltais I,

Marceau F, et al. Altered frequency of a promoter polymorphism
of the kinin B2 receptor gene in hypertensive African-
Americans. Am J Hypertens. 2000;13:1268–1273.

263 Wang B, Dang A, Liu G. Genetic variation in the promoter

region of the beta2 bradykinin receptor gene is associated with
essential hypertension in a Chinese Han population. Hypertens
Res. 2001;24:299–302.

264 Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T.

Bradykinin B(2) receptor gene polymorphism is associated with
angiotensin-converting enzyme inhibitor-related  cough. Hyper-
tension. 2000;36:127–131.

265 Zychma MJ, Gumprecht J, Trautsolt W, Szydlowska I,

Grzeszczak W. Polymorphic genes for kinin receptors, nephro-
pathy and blood pressure in type 2 diabetic patients. Am J
Nephrol. 2003;23:112–116.

266 Bachvarov DR, Landry M, Pelletier I, Chevrette M, Betard C,

The Kallikrein-Kinin System

37

Houde I, et al. Characterization of two polymorphic sites in the
human kinin B1 receptor gene: altered frequency of an allele in
patients with a history of end-stage renal failure. J Am Soc
Nephrol. 1998;9:598–604.

267 Bachvarov DR, Landry M, Houle S, Pare P, Marceau F. Altered

frequency of a promoter polymorphic allele of the kinin B1
receptor gene in inflammatory bowel disease. Gastroenterology.
1998;115:1045–1048.

268 Ueno A, Oh-ishi S. Roles for the kallikrein-kinin system in

inflammatory exudation and pain: lessons from studies on
kininogen-deficient rats. J Pharmacol Sci. 2003;93:1–20.

269 Akbary AM, Wirth KJ, Scholkens BA. Efficacy and tolerability

of Icatibant (Hoe 140) in patients with moderately severe
chronic bronchial asthma. Immunopharmacology. 1996;33:238–
242.

270 Turner P, Dear J, Scadding G, Foreman JC. Role of kinins in

seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor
antagonist, abolishes the hyperresponsiveness and nasal eosino-
philia induced by antigen. J Allergy Clin Immunol. 2001;107:
105–113.

271 Proud D, Bathon JM, Togias AG, Naclerio RM. Inhibition of the

response to nasal provocation with bradykinin by HOE-140:
efficacy and duration of action. Can J Physiol Pharmacol.
1995;73:820–826.

272 Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr,

Knaus WA, et al. Treatment of severe systemic inflammatory
response syndrome and sepsis with a novel bradykinin antago-
nist, deltibant (CP-0127). Results of a randomized, double-blind,
placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.
Jama. 1997;277:482–487.

273 Heitsch H. The therapeutic potential of bradykinin B2 receptor

agonists in the treatment of cardiovascular disease. Expert Opin
Investig Drugs. 2003;12:759–770.

274 Groves P, Kurz S, Just H, Drexler H. Role of endogenous brady-

kinin in human coronary vasomotor control. Circulation. 1995;
92:3424–3430.

275 Regoli DC, Marceau F, Lavigne J. Induction of beta 1-receptors

for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J
Pharmacol. 1981;71:105–115.

276 deBlois D, Horlick RA. Endotoxin sensitization to kinin B(1)

receptor agonist in a non-human primate model: haemodynamic
and pro-inflammatory effects. Br J Pharmacol. 2001;132:327–
335.

277 Ignarro LJ, Byrns RE, Buga GM, Wood KS. Mechanisms of

endothelium-dependent vascular smooth muscle relaxation elicited

by bradykinin and VIP. Am J Physiol. 1987;253:H1074–H1082.

278 Zhu P, Zaugg CE, Hornstein PS, Allegrini PR, Buser PT. Brady-

kinin-dependent cardioprotective effects of losartan against
ischemia and reperfusion in rat hearts. J Cardiovasc Pharmacol.
1999;33:785–790.

279 Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE.

Bradykinin contributes to the vasodilator effects of chronic
angiotensin-converting enzyme inhibition in patients with heart
failure. Circulation. 2001;104:2177–2181.

280 Lagneux C, Adam A, Lamontagne D. A study of the mediators

involved in the protection induced by exogenous kinins in the
isolated rat heart. Int Immunopharmacol. 2003;3:1511–1518.

281 Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R,

Isner JM, et al. Targeting kinin B(1) receptor for therapeutic
neovascularization. Circulation. 2002;105:360–366.

282 Aramori I, Zenkoh J, Morikawa N, O’Donnell N, Asano M,

Nakamura K, et al. Novel subtype-selective nonpeptide brady-
kinin receptor antagonists FR167344 and FR173657. Mol
Pharmacol. 1997;51:171–176.

283 Majima M, Hayashi I, Inamura N, Fujita T, Ogino M. A non-

peptide mimic of bradykinin blunts the development of hyper-
tension in young spontaneously hypertensive rats. Hypertension.
2000;35:437–442.

284 Emerich DF, Dean RL, Osborn C, Bartus RT. The development

of the bradykinin agonist labradimil as a means to increase the
permeability of the blood-brain barrier: from concept to clinical
evaluation. Clin Pharmacokinet. 2001;40:105–123.

285 Liesmaa I, Kuoppala A, Shiota N, Kokkonen JO, Kostner K,

Mayranpaa M, et al. Increased expression of bradykinin type-1
receptors in endothelium of intramyocardial coronary vessels in
human failing hearts. Am J Physiol Heart Circ Physiol.
2005;288:H2317–H2322.

286 Decarie A, Adam A, Couture R. Effects of captopril and

Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-
induced edema. Peptides. 1996;17:1009–1015.

287 Cruwys SC, Garrett NE, Perkins MN, Blake DR, Kidd BL. The

role of bradykinin B1 receptors in the maintenance of intra-

articular plasma extravasation in chronic antigen-induced arthritis

.

Br J Pharmacol. 1994;113:940–944.

288 Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA

Jr, Walther T, et al. Hypoalgesia and altered inflammatory
responses in mice lacking kinin B1 receptors. Proc Natl Acad
Sci U S A. 2000;97:8140–8145.

289 Dray A, Patel IA, Perkins MN, Rueff A. Bradykinin-induced

activation of nociceptors: receptor and mechanistic studies on
the neonatal rat spinal cord-tail preparation in vitro. Br J
Pharmacol. 1992;107:1129–1134.

290 Dray A. Kinins and their receptors in hyperalgesia. Can J

Physiol Pharmacol. 1997;75:704–712.

291 Belichard P, Landry M, Faye P, Bachrarov DR, Bouthillier J,

Druneau D, et al. Inflammatory hyperalgesia induced by
zymosan in the plantar tissue of the rat: effect of kinin receptor
antagonists. Immunopharmacology. 2000;46:139–147.

292 Burgess GM, Perkins MN, Rang HP, Campbell EA, Brown MC,

McIntyre P, et al. Bradyzide, a potent non-peptide B(2) bradyki-
nin receptor antagonist with long-lasting oral activity in animal
models of inflammatory hyperalgesia. Br J Pharmacol. 2000;
129:77–86.

293 Ma QP, Heavens R. Basal expression of bradykinin B1 receptor

in the spinal cord in humans and rats. Neuroreport. 2001;12:
2311–2314.

294 Wotherspoon G, Winter J. Bradykinin B1 receptor is constitu-

tively expressed in the rat sensory nervous system. Neurosci
Lett. 2000;294:175–178.

295 Shughrue PJ, Ky B, Austin CP. Localization of B1 bradykinin

receptor mRNA in the primate brain and spinal cord: an in situ
hybridization study. J Comp Neurol. 2003;465:372–384.

296 Ongali B, Campos MM, Petcu M, Rodi D, Cloutier F, Chabot

JG, et al. Expression of kinin B1 receptors in the spinal cord of
streptozotocin-diabetic rat. Neuroreport. 2004;15:2463–2466.

297 Zausinger S, Lumenta DB, Pruneau D, Schmid-Elsaesser R,

Plesnila N, Baethmann A. Therapeutical efficacy of a novel
non-peptide bradykinin B2 receptor antagonist on brain edema
formation and ischemic tissue damage in focal cerebral
ischemia. Acta Neurochir Suppl. 2003;86:205–207.

298 Zausinger S. Bradykinin receptor antagonists in cerebral

ischemia and trauma. IDrugs. 2003;6:970–975.

ME Moreau et al

38

299 Prat A, Biernacki K, Pouly S, Nalbantoglu J, Couture R, Antel

JP. Kinin B1 receptor expression and function on human brain
endothelial cells. J Neuropathol Exp Neurol. 2000;59:896–906.

300 Prat A, Weinrib L, Becher B, Poirier J, Duquette P, Couture R,

et al. Bradykinin B1 receptor expression and function on T
lymphocytes in active multiple sclerosis. Neurology. 1999;53:
2087–2092.

301 Bregola G, Varani K, Gessi S, Beani L, Bianchi C, Borea PA,

et al. Changes in hippocampal and cortical B1 bradykinin
receptor biological activity in two experimental models of
epilepsy. Neuroscience. 1999;92:1043–1049.

302 Jaggar SI, Habib S, Rice AS. The modulatory effects of brady-

kinin B1 and B2 receptor antagonists upon viscero-visceral
hyper-reflexia in a rat model of visceral hyperalgesia. Pain.
1998;75:169–176.

303 Stadnicki A, Pastucha E, Nowaczyk G, Mazurek U, Plewka D,

Machinik G, et al. Immunolocalization and expression of kinin
B1R and B2R receptors in human inflammatory bowel disease.
Am J Physiol Gastrointest Liver Physiol. 2005;289:G361–G366.

304 Gabra BH, Sirois P. Kinin B1 receptor antagonists inhibit

diabetes-induced hyperalgesia in mice. Neuropeptides. 2003;37:
36–44.

305 Gabra BH, Sirois P. Beneficial effect of chronic treatment with

the selective bradykinin B1 receptor antagonists, R-715 and R-
954, in attenuating streptozotocin-diabetic thermal hyperalgesia
in mice. Peptides. 2003;24:1131–1139.

306 Zuccollo A, Navarro M, Frontera M, Cueva F, Carattino M,

Catanzaro OL. The involvement of kallikrein-kinin system in

diabetes type I (insulitis). Immunopharmacology. 1999;45:69–74

.

307 Cloutier F, Couture R. Pharmacological characterization of the

cardiovascular responses elicited by kinin B(1) and B(2)
receptor agonists in the spinal cord of streptozotocin-diabetic
rats. Br J Pharmacol. 2000;130:375–385.

308 Campos MM, Cabrini DA, Cardozo AH, Rae GA, Toro JH,

Calixto JB. Changes in paw oedema triggered via bradykinin
B(1) and B(2) receptors in streptozotocin-diabetic rats. Eur J
Pharmacol. 2001;416:169–177.

309 Gabra BH, Sirois P. Role of bradykinin B(1) receptors in

diabetes-induced hyperalgesia in streptozotocin-treated mice.
Eur J Pharmacol. 2002;457:115–124.

310 Wang CH, Leung N, Lapointe N, Szeto L, Uffelman KD, Giacca

A, et al. Vasopeptidase inhibitor omapatrilat induces profound
insulin sensitization and increases myocardial glucose uptake in
Zucker fatty rats: studies comparing a vasopeptidase inhibitor,
angiotensin-converting enzyme Inhibitor, and angiotensin II type
I receptor blocker. Circulation. 2003;107:1923–1929.

311 Shiuchi T, Nakagami H, Iwai M, Takeda Y, Cui T, Chen R, et al.

Involvement of bradykinin and nitric oxide in leptin-mediated
glucose uptake in skeletal muscle. Endocrinology. 2001;142:
608–612.

312 Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. Effect of

high salt intake in mutant mice lacking bradykinin-B2 receptors.
Hypertension. 1997;29:483–487.

313 Margolius HS. Theodore Cooper Memorial Lecture. Kallikreins

and kinins. Some unanswered questions about system character-
istics and roles in human disease. Hypertension. 1995;26:221–

229.

314 Couture R, Girolami JP. Putative roles of kinin receptors in the

therapeutic effects of angiotensin 1-converting enzyme inhibitors
in diabetes mellitus. Eur J Pharmacol. 2004;500:467–485.

315 Regoli D, Barabe J. Pharmacology of bradykinin and related

kinins. Pharmacol Rev. 1980;32:1–46.

316 Berkin KE. Respiratory effects of angiotensin converting

enzyme inhibition. Eur Respir J. 1989;2:198–201.

317 Levy D, Zochodne DW. Increased mRNA expression of the B1

and B2 bradykinin receptors and antinociceptive effects of their
antagonists in an animal model of neuropathic pain. Pain.
2000;86:265–271.

318 Drapeau G, Audet R, Levesque L, Godin D, Marceau F.

Development and in vivo evaluation of metabolically resistant
antagonists of B1 receptors for kinins. J Pharmacol Exp Ther.
1993;266:192–199.

319 Eric J, Gabra BH, Sirois P. Implication of the bradykinin

receptors in antigen-induced pulmonary inflammation in mice.
Br J Pharmacol. 2003;138:1589–1597.

320 Gera L, Stewart JM, Whalley ET, Burkard M, Zuzack JS. New

bradykinin antagonists having very high potency at B1 receptors.
Immunopharmacology. 1996;33:183–185.

321 Rhaleb NE, Gobeil F, Regoli D. Non-selectivity of new brady-

kinin antagonists for B1 receptors. Life Sci. 1992;51:PL125–
PL129.

322 Burkard M, Zuzack JS, Jones S, Francis M, Whalley ET, Stewart

JM, et al. Comparative profile of novel potent bradykinin

antagonists at human B1 and B2 receptors. Immunopharmacology

.

1996;33:186–190.

323 Gama Landgraf R, Jancar S, Steil AA, Sirois P. Modulation of

allergic and immune complex-induced lung inflammation by
bradykinin receptor antagonists. Inflamm Res. 2004;53:78–83.

324 Christiansen SC, Eddleston J, Woessner KM, Chambers SS, Ye

R, Pan ZK, et al. Up-regulation of functional kinin B1 receptors
in allergic airway inflammation. J Immunol. 2002;169:2054–
2060.

325 Austin CE, Foreman JC. A study of the action of bradykinin and

bradykinin analogues in the human nasal airway. J Physiol
(Lond). 1994;478:351–356.

326 Asano M, Hatori C, Inamura N, Sawai H, Hirosumi J, Fujiwara

T, et al. Effects of a nonpeptide bradykinin B2 receptor
antagonist, FR167344, on different in vivo animal models of
inflammation. Br J Pharmacol. 1997;122:1436–1440.

327 Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Inamura N,

et al. A novel class of orally active non-peptide bradykinin B2
receptor antagonists. 2. Overcoming the species difference
between guinea pig and man. J Med Chem. 1998;41:4053–4061.

328 Youngman MA, Carson JR, Lee JS, Dax SL, Zhang SP, Colburn

RW, et al. Synthesis and structure – activity relationships of
aroylpyrrole alkylamide bradykinin (B2) antagonists. Bioorg
Med Chem Lett. 2003;13:1341–1344.

329 Lam YKT, Hensens OD, Ransom R, Giacobbe RA, Polishook J,

Zink D. L-755,807, A New Non-Peptide Bradykinin Binding
Inhibitor From An Endophytic Microsphaeropsis Sp. Tetra-
hedron. 1996;52:1481–1486.